Citations 1
Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
Chen, Huanwen , McIntyre, Matthew K. , Kakadiya, Jay , Rai, Pranjal , Essibayi, Muhammed Amir , Salim, Hamza , Mandel, Daniel M, Buzzeli, Marc, Yedavalli, Vivek , Gandhi, Dheeraj, Azzam, Ahmed Y , Essibayi, Muhammed Amir , Salim, Hamza , Yedavalli, Vivek S , Dmytriw, Adam A , Malhotra, Ajay , Colasurdo, Marco , Lakhani, Dhairya , Kakadiya, Jay , Rai, Pranjal , Dmytriw, Adam A. , Malhotra, Ajay , Gandhi, Dheeraj , Colasurdo, Marco , Lakhani, Dhairya A.
Neurosurgery | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.